Kang Yu

Kangyu Biotech (K-Bio) is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the discovery and development of next-generation multispecific antibody therapeutics. The company leverages its proprietary M-Body platform to engineer antibodies with enhanced potency and safety profiles, primarily targeting hematological malignancies and solid tumors. Its lead candidate, KY-0118, is a CD38/CD3 bispecific antibody currently in Phase 1 clinical trials for the treatment of relapsed or refractory multiple myeloma. K-Bio's pipeline also includes several preclinical programs targeting BCMA, GPRC5D, and other validated oncology targets. The company was founded by industry veterans with extensive experience in antibody engineering and drug development.